4D Molecular Therapeutics Inc
4D Molecular Therapeutics (FDMT) is a clinical-stage biotechnology company developing targeted adeno-associated virus (AAV) gene therapies. The firm uses an engineered AAV platform — informed by directed evolution and design — to aim delivery to specific tissues such as the eye, central nervous system and liver, seeking treatments for rare genetic and metabolic disorders. As a research-led company with a market capitalisation around $525m, its value depends heavily on clinical trial outcomes, regulatory decisions and potential partnerships or licensing deals. Investors should expect volatility typical of small-cap biotech stocks: programmes can advance or fail, and further fundraising or dilution is possible. This is general educational information, not investment advice; consider your risk tolerance and time horizon and consult a professional before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying 4D Molecular Therapeutics Inc's stock with a target price of $33.11, indicating significant growth potential.
Financial Health
4D Molecular Therapeutics Inc has low revenue and cash flow, indicating financial struggles.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring FDMT
Injectable Drug Innovation Opportunities 2025
The FDA's approval of an at-home injectable version of Eisai and Biogen's Alzheimer's drug, Leqembi, simplifies treatment for patients and caregivers. This development highlights a growing trend toward patient-centric care, creating investment opportunities in companies that specialize in innovative drug delivery systems and at-home therapeutic technologies.
Published: August 31, 2025
Explore BasketNext-Generation Drug Delivery Systems
This carefully selected group of stocks represents innovative companies revolutionizing how medications are delivered to patients. Handpicked by our professional analysts, these firms are developing technologies that make treatments simpler, more effective, and user-friendly, creating meaningful investment potential in an evolving healthcare landscape.
Published: July 18, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Engineered AAV platform
Directed-evolution and design aim to improve tissue targeting; clinical proof is required and outcomes can vary.
Catalysts to watch
Clinical readouts, regulatory milestones and partnership announcements can move the stock, but they also bring heightened volatility.
Niche disease focus
Concentrating on rare genetic and metabolic disorders may mean meaningful clinical impact if successful, though patient numbers and reimbursement can limit commercial scale.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
